Chemokine-like factor-like MARVEL transmembrane domain-containing family in autoimmune diseases.
Journal
Chinese medical journal
ISSN: 2542-5641
Titre abrégé: Chin Med J (Engl)
Pays: China
ID NLM: 7513795
Informations de publication
Date de publication:
20 Apr 2020
20 Apr 2020
Historique:
pubmed:
21
3
2020
medline:
2
2
2021
entrez:
21
3
2020
Statut:
ppublish
Résumé
The chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM) is widely expressed in the immune system. Abnormal expression of CMTM is associated with the development of various diseases. This article summarizes the relevant research on the role of the CMTM family in immune disorders. This information will increase our understanding of pathogenesis and identify promising targets for the diagnosis and treatment of autoimmune diseases. The CMTM family is highly expressed in peripheral blood mononuclear cells. CKLF1 may be involved in the development of arthritis through its interaction with C-C chemokine receptor 4. CKLF1 is associated with the pathogenesis of lupus nephritis and psoriasis. Both CMTM4 and CMTM5 are associated with the pathogenesis of systemic lupus erythematosus. CMTM1, CMTM2, CMTM3, and CMTM6 play a role in rheumatoid arthritis, systemic sclerosis, Sjögren syndrome, and anti-phospholipid syndrome, respectively. The CMTM family has been implicated in various autoimmune diseases. Further research on the mechanism of the action of CMTM family members may lead to the development of new treatment strategies for autoimmune diseases.
Identifiants
pubmed: 32195671
doi: 10.1097/CM9.0000000000000747
pmc: PMC7176445
pii: 00029330-202004200-00009
doi:
Substances chimiques
CMTM4 protein, human
0
CMTM5 protein, human
0
Chemokines
0
MARVEL Domain-Containing Proteins
0
Tumor Suppressor Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
951-958Références
Han W, Lou Y, Tang J, Zhang Y, Chen Y, Li Y, et al. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J 2001; 357:127–135. doi: 10.1042/0264-6021:3570127.
doi: 10.1042/0264-6021:3570127
Han W, Ding P, Xu M, Wang L, Rui M, Shi S, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics 2003; 81:609–617. doi: 10.1016/s0888-7543(03)00095-8.
doi: 10.1016/s0888-7543(03)00095-8
Harris SL, Thorne LB, Seaman WT, Hayes DN, Couch ME, Kimple RJ. Association of p16(INK4a) overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck 2011; 33:1622–1627. doi: 10.1002/hed.21650.
doi: 10.1002/hed.21650
Zhong J, Wang Y, Qiu X, Mo X, Liu Y, Li T, et al. Characterization and expression profile of CMTM3/CKLFSF3. J Biochem Mol Biol 2006; 39:537–545. doi: 10.5483/bmbrep.2006.39.5.537.
doi: 10.5483/bmbrep.2006.39.5.537
Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem 1997; 272:15036–15042. doi: 10.1074/jbc.272.23.15036.
doi: 10.1074/jbc.272.23.15036
Imai T, Chantry D, Raport CJ, Wood CL, Nishimura M, Godiska R, et al. Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J Biol Chem 1998; 273:1764–1768. doi: 10.1074/jbc.273.3.1764.
doi: 10.1074/jbc.273.3.1764
Wang Y, Zhang YM, Yang X, Han WL, Liu YN, Xu QM, et al. Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4). Life Sci 2006; 78:614–621. doi: 10.1016/j.lfs.2005.05.070.
doi: 10.1016/j.lfs.2005.05.070
Wang Y, Zhang Y, Yang X, Han W, Liu Y, Xu Q, et al. Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4). Life Sci 2006; 78:614–621. doi: 10.1016/j.lfs.2005.05.070.
doi: 10.1016/j.lfs.2005.05.070
Clark-Lewis I, Kim KS, Rajarathnam K, Gong JH, Dewald B, Moser B, et al. Structure-activity relationships of chemokines. J Leukoc Biol 1995; 57:703–711. doi: 10.1002/jlb.57.5.703.
doi: 10.1002/jlb.57.5.703
D’Ambrosio D, Panina-Bordignon P, Sinigaglia F. Chemokine receptors in inflammation: an overview. J Immunol Methods 2003; 273:3–13. doi: 10.1016/S0022-1759(02)00414-3.
doi: 10.1016/s0022-1759(02)00414-3
Ke X, Jia L, Jing H, Liu Y, Zhang Y, Di C. Effects of novel human chemokine-like factor 1 (CKLF1) on bone marrow hematopoietic stem cell/progenitor cell in vitro (in Chinese). Chin J Hematol 2002; 23:301–303.
Licastro F, Davis LJ, Morini MC. Lectins and superantigens - membrane interactions of these compounds with T-lymphocytes affect immune-responses. Int J Biochem 1993; 25:845–852. doi: 10.1016/0020-711x(93)90239-B.
doi: 10.1016/0020-711x(93)90239-b
Fan J, Nishanian P, Breen EC, McDonald M, Fahey JL. Cytokine gene expression in normal human lymphocytes in response to stimulation. Clin Diagn Lab Immun 1998; 5:335–340. doi: 10.1089/aid.1998.14.639.
doi: 10.1089/aid.1998.14.639
Li T, Zhong J, Chen YY, Qiu XY, Zhang T, Ma DL, et al. Expression of chemokine-like factor 1 is upregulated during T lymphocyte activation. Life Sci 2006; 79:519–524. doi: 10.1016/j.lfs.2006.01.042.
doi: 10.1016/j.lfs.2006.01.042
Kong LL, Wang ZY, Han N, Zhuang XM, Wang ZZ, Li H, et al. Neutralization of chemokine-like factor 1, a novel C-C chemokine, protects against focal cerebral ischemia by inhibiting neutrophil infiltration via MAPK pathways in rats. J Neuroinflammation 2014; 11:112doi: 10.1186/1742-2094-11-112.
doi: 10.1186/1742-2094-11-112
Shao L, Li T, Mo X, Majdic O, Zhang Y, Seyerl M, et al. Expressional and functional studies of CKLF1 during dendritic cell maturation. Cell Immunol 2010; 263:188–195. doi: 10.1016/j.cellimm.2010.03.015.
doi: 10.1016/j.cellimm.2010.03.015
Dai SY, Nakagawa R, Itoh A, Murakami H, Kashio Y, Abe H, et al. Galectin-9 induces maturation of human monocyte-derived dendritic cells. J Immunol 2005; 175:2974–2981. doi: 10.4049/jimmunol.175.5.2974.
doi: 10.4049/jimmunol.175.5.2974
Li G, Wang D, Sun M, Li G, Hu J, Zhang Y, et al. Discovery and optimization of novel 3-piperazinylcoumarin antagonist of chemokine-like factor 1 with oral antiasthma activity in mice. J Med Chem 2010; 53:1741–1754. doi: 10.1021/jm901652p.
doi: 10.1021/jm901652p
Sun M, Hu J, Song X, Wu D, Kong L, Sun Y, et al. Coumarin derivatives protect against ischemic brain injury in rats. Eur J Med Chem 2013; 67:39–53. doi: 10.1016/j.ejmech.2013.04.015.
doi: 10.1016/j.ejmech.2013.04.015
Ai Q, Chen C, Chu S, Luo Y, Zhang Z, Zhang S, et al. IMM-H004 protects against cerebral ischemia injury and cardiopulmonary complications via CKLF1 mediated inflammation pathway in adult and aged rats. Int J Mol Sci 2019; 20:E1661doi: 10.3390/ijms20071661.
doi: 10.3390/ijms20071661
Kim CH, Lim HW, Kim JR, Rott L, Hillsamer P, Butcher EC. Unique gene expression program of human germinal center T helper cells. Blood 2004; 104:1952–1960. doi: 10.1182/blood-2004-03-1206.
doi: 10.1182/blood-2004-03-1206
Wang Y, Zhang Y, Han W, Li D, Tian L, Yin C, et al. Two C-terminal peptides of human CKLF1 interact with the chemokine receptor CCR4. Int J Biochem Cell Biol 2008; 40:909–919. doi: 10.1016/j.biocel.2007.10.028.
doi: 10.1016/j.biocel.2007.10.028
Liu Y, Zhang S, Ling X, Li Y, Zhang Y, Han W, et al. Analysis of the interactions between the peptides from secreted human CKLF1 and heparin using capillary zone electrophoresis. J Pept Sci 2008; 14:984–988. doi: 10.1002/psc.1028.
doi: 10.1002/psc.1028
Zhang Y, Tian L, Zheng Y, Qi H, Guo C, Sun Q, et al. C-terminal peptides of chemokine-like factor 1 signal through chemokine receptor CCR4 to cross-desensitize the CXCR4. Biochem Biophys Res Commun 2011; 409:356–361. doi: 10.1016/j.bbrc.2011.05.047.
doi: 10.1016/j.bbrc.2011.05.047
Shao LN, Li T, Mo XN, Majdic O, Zhang YF, Seyerl M, et al. Expressional and functional studies of CKLF1 during dendritic cell maturation. Cell Immunol 2010; 263:188–195. doi: 10.1016/j.cellimm.2010.03.015.
doi: 10.1016/j.cellimm.2010.03.015
Zheng Y, Guo CY, Zhang Y, Qi H, Sun QY, Xu EQ, et al. Alleviation of murine allergic rhinitis by C19, a C-terminal peptide of chemokine-like factor 1 (CKLF1). Int Immunopharmacol 2011; 11:2188–2193. doi: 10.1016/j.intimp.2011.09.017.
doi: 10.1016/j.intimp.2011.09.017
Li T, Zhong J, Chen Y, Qiu X, Zhang T, Ma D, et al. Expression of chemokine-like factor 1 is upregulated during T lymphocyte activation. Life Sci 2006; 79:519–524. doi: 10.1016/j.lfs.2006.01.042.
doi: 10.1016/j.lfs.2006.01.042
Lu J, Wu QQ, Zhou YB, Zhang KH, Pang BX, Li L, et al. Cancer research advance in CKLF-like MARVEL transmembrane domain containing member family (review). Asian Pac J Cancer Prev 2016; 17:2741–2744.
Wang L, Wu C, Zheng Y, Qiu X, Wang L, Fan H, et al. Molecular cloning and characterization of chemokine-like factor super family member 1 (CKLFSF1), a novel human gene with at least 23 alternative splicing isoforms in testis tissue. Int J Biochem Cell Biol 2004; 36:1492–1501. doi: 10.1016/j.biocel.2003.11.017.
doi: 10.1016/j.biocel.2003.11.017
Si J, Zhang P, Tian D, Wang X, Ma Y, Zhang J, et al. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer. World J Surg Oncol 2017; 15:34doi: 10.1186/s12957-016-1094-z.
doi: 10.1186/s12957-016-1094-z
Shi S, Rui M, Han W, Wang Y, Qiu X, Ding P, et al. CKLFSF2 is highly expressed in testis and can be secreted into the seminiferous tubules. Int J Biochem Cell Biol 2005; 37:1633–1640. doi: 10.1016/j.biocel.2004.04.028.
doi: 10.1016/j.biocel.2004.04.028
Song HS, Shi SA, Lu XZ, Gao F, Yan L, Wang Y, et al. Intracellular CMTM2 negatively regulates human immunodeficiency virus type-1 transcription through targeting the transcription factors AP-1 and CREB. Chin Med J 2010; 123:2440–2445. doi: 10.3760/cma.j.issn.0366-6999.2010.17.027.
doi: 10.3760/cma.j.issn.0366-6999.2010.17.027
Liu B, Li H, Fu W, Cheng Y, Yuan W, Liu W, et al. CMTM3 presents a secreted form released via exosomes. Acta Biochim Biophys Sin (Shanghai) 2016; 48:584–586. doi: 10.1093/abbs/gmw029.
doi: 10.1093/abbs/gmw029
Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 2017; 549:106–110. doi: 10.1038/nature23669.
doi: 10.1038/nature23669
Li P, Liu K, Li L, Yang MX, Gao WJ, Feng JB, et al. Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer. Int J Gynecol Cancer 2011; 21:1248–1255. doi: 10.1097/IGC.0b013e3182259c31.
doi: 10.1097/igc.0b013e3182259c31
Liu PC, Barb J, Woodhouse K, Taylor JG, Munson PJ, Raghavachari N. Transcriptome profiling and sequencing of differentiated human hematopoietic stem cells reveal lineage-specific expression and alternative splicing of genes. Physiol Genomics 2011; 43:1117–1134. doi: 10.1152/physiolgenomics.00099.2011.
doi: 10.1152/physiolgenomics.00099.2011
Li HN, Guo XH, Shao LN, Plate M, Mo XN, Wang Y, et al. CMTM5-v1, a four-transmembrane protein, presents a secreted form released via a vesicle-mediated secretory pathway. BMB Rep 2010; 43:182–187. doi: 10.5483/BMBRep.2010.43.3.182.
doi: 10.5483/bmbrep.2010.43.3.182
Yafune A, Kawai M, Itahashi M, Kimura M, Nakane F, Mitsumori K, et al. Global DNA methylation screening of liver in piperonyl butoxide-treated mice in a two-stage hepatocarcinogenesis model. Toxicol Lett 2013; 222:295–302. doi: 10.1016/j.toxlet.2013.08.006.
doi: 10.1016/j.toxlet.2013.08.006
Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 2017; 549:101–105. doi: 10.1038/nature23643.
doi: 10.1038/nature23643
Zhang Y, Wang JY, Han W. A role for CMTM7 in BCR expression and survival in B-1a but not B-2 cells. Int Immunol 2014; 26:47–57. doi: 10.1093/intimm/dxt042.
doi: 10.1093/intimm/dxt042
Miyazaki A, Yogosawa S, Murakami A, Kitamura D. Identification of CMTM7 as a transmembrane linker of BLNK and the B-Cell receptor. Plos One 2012; 7:e31829doi: 10.1371/journal.pone.0031829.
doi: 10.1371/journal.pone.0031829
Liu Z, Liu Y, Li T, Wang P, Mo X, Lv P, et al. Cmtm7 knockout inhibits B-1a cell development at the transitional (TrB-1a) stage. Int Immunol 2019; 31:715–728. doi: 10.1093/intimm/dxz041.
doi: 10.1093/intimm/dxz041
Youinou P, Mackenzie L, Katsikis P, Merdrignac G, Isenberg DA, Tuaillon N, et al. The relationship between CD5-expressing B lymphocytes and serologic abnormalities in rheumatoid arthritis patients and their relatives. Arthritis Rheum 1990; 33:339–348. doi: 10.1002/art.1780330306.
doi: 10.1002/art.1780330306
Jin C, Ding P, Wang Y, Ma D. Regulation of EGF receptor signaling by the MARVEL domain-containing protein CKLFSF8. FEBS Lett 2005; 579:6375–6382. doi: 10.1016/j.febslet.2005.10.021.
doi: 10.1016/j.febslet.2005.10.021
Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med 2015; 278:369–395. doi: 10.1111/joim.12395.
doi: 10.1111/joim.12395
La Paglia GMC, Leone MC, Lepri G, Vagelli R, Valentini E, Alunno A, et al. One year in review 2017: systemic lupus erythematosus. Clin Exp Rheumatol 2017; 35:551–561.
Aringer M, Schneider M. Systemic lupus erythematosus. Dtsch Med Wochenschr 2016; 141:537–543. doi: 10.1055/s-0041-110604.
doi: 10.1055/s-0041-110604
Alarcon GS. Multiethnic lupus cohorts: what have they taught us? Reumatol Clin 2011; 7:3–6. doi: 10.1016/j.reuma.2010.11.001.
doi: 10.1016/j.reuma.2010.11.001
Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol 2017; 12:825–835. doi: 10.2215/CJN.05780616.
doi: 10.2215/cjn.05780616
Bethunaickan R, Berthier CC, Zhang W, Eksi R, Li HD, Guan YF, et al. Identification of stage-specific genes associated with lupus nephritis and response to remission induction in NZB/W and NZM2410 mice. Arthritis Rheumatol 2014; 66:2246–2258. doi: 10.1002/art.38679.
doi: 10.1002/art.38679
Vielhauer V, Anders HJ, Schlondorff D. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis. Semin Nephrol 2007; 27:81–97. doi: 10.1016/j.semnephrol.2006.09.010.
doi: 10.1016/j.semnephrol.2006.09.010
Ji Y, Zhang H, Yuan H, Yang GP, Zhang K, Xie LH. Expression of chemokine like factor-1 in nephridial tissue of lupus nephritis (in Chinese). J Central South Univ (Med Ed) 2007; 32:490–493.
Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376:1094–1108. doi: 10.1016/S0140-6736(10)60826-4.
doi: 10.1016/s0140-6736(10)60826-4
Klarenbeek PL, de Hair MJ, Doorenspleet ME, van Schaik BD, Esveldt RE, van de Sande MG, et al. Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann Rheum Dis 2012; 71:1088–1093. doi: 10.1136/annrheumdis-2011-200612.
doi: 10.1136/annrheumdis-2011-200612
James EA, Rieck M, Pieper J, Gebe JA, Yue BB, Tatum M, et al. Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol 2014; 66:1712–1722. doi: 10.1002/art.38637.
doi: 10.1002/art.38637
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205–2219. doi: 10.1056/NEJMra1004965.
doi: 10.1056/nejmra1004965
Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223:7–19. doi: 10.1111/j.1600-065X.2008.00626.x.
doi: 10.1111/j.1600-065x.2008.00626.x
Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet 2019; 393:1745–1759. doi: 10.1016/S0140-6736(19)30417-9.
doi: 10.1016/s0140-6736(19)30417-9
Martel-Pelletier J, Wildi LM, Pelletier JP. Future therapeutics for osteoarthritis. Bone 2012; 51:297–311. doi: 10.1016/j.bone.2011.10.008.
doi: 10.1016/j.bone.2011.10.008
Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in-situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing-spondylitis. Arthritis Rheum 1995; 38:499–505. doi: 10.1002/art.1780380407.
doi: 10.1002/art.1780380407
Borzi RM, Mazzetti I, Cattini L, Uguccioni M, Baggiolini M, Facchini A. Human chondrocytes express functional chemokine receptors and release matrix-degrading enzymes in response to C-X-C and C-C chemokines. Arthritis Rheum 2000; 43:1734–1741. doi: 10.1002/1529-0131(200008)43:8<1734::Aid-Anr9>3.0.Co;2-B.
doi: 10.1002/1529-0131(200008)43:8<1734::aid-anr9>3.0.co;2-b
Rioja I, Clayton CL, Graham SJ, Life PF, Dickson MC. Gene expression profiles in the rat streptococcal cell wall-induced arthritis model identified using microarray analysis. Arthritis Res Ther 2005; 7:R101–R117. doi: 10.1186/ar1458.
doi: 10.1186/ar1458
Tao K, Tang X, Wang B, Li RJ, Zhang BQ, Lin JH, et al. Distinct expression of chemokine-like factor 1 in synovium of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. J Huazhong Univ Sci-Med 2016; 36:70–76. doi: 10.1007/s11596-016-1544-4.
doi: 10.1007/s11596-016-1544-4
Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107:7–11. doi: 10.1172/JCI11830.
doi: 10.1172/jci11830
Keith JC, Albert LM, Leathurby Y, Follettie M, Wang LL, Borges-Marcucci L, et al. The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther 2005; 7:R427–R438. doi: 10.1186/ar1692.
doi: 10.1186/ar1692
Cheng A, Han W, Ma D, Lou S. Effects of chemokine-like factor 1 (CKLF1) on proliferation and metabolism of chondrocytes (in Chinese). J Peking Univ (Healt Sci) 2003; 35:399–401. doi: 10.1142/S0252959903000104.
doi: 10.1142/s0252959903000104
MacDonald A, Burden AD. Psoriasis: advances in pathophysiology and management. Postgrad Med J 2007; 83:690–697. doi: 10.1136/pgmj.2007.061473.
doi: 10.1136/pgmj.2007.061473
Tan Y, Wang Y, Li L, Xia J, Peng S, He Y. Chemokine-like factor 1-derived C-terminal peptides induce the proliferation of dermal microvascular endothelial cells in psoriasis. PLoS One 2015; 10:e0125073doi: 10.1371/journal.pone.0125073.
doi: 10.1371/journal.pone.0125073
Clapham DE. Calcium signaling. Cell 2007; 131:1047–1058. doi: 10.1016/j.cell.2007.11.028.
doi: 10.1016/j.cell.2007.11.028
Izquierdo JH, Bonilla-Abadia F, Canas CA, Tobon GJ. Calcium, channels, intracellular signaling and autoimmunity. Reumatol Clin 2014; 10:43–47. doi: 10.1016/j.reuma.2013.05.008.
doi: 10.1016/j.reuma.2013.05.008
Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233:233–255. doi: 10.1111/j.0105-2896.2009.00859.x.
doi: 10.1111/j.0105-2896.2009.00859.x
de Seabra Rodrigues Dias IR, Mok SWF, Gordillo-Martinez F, Khan I, Hsiao WWL, Law BYK, et al. The calcium-induced regulation in the molecular and transcriptional circuitry of human inflammatory response and autoimmunity. Front Pharmacol 2017; 8:962doi: 10.3389/fphar.2017.00962.
doi: 10.3389/fphar.2017.00962
Wong VKW, Qiu C, Xu SW, Law BYK, Zeng W, Wang H, et al. Ca(2+) signalling plays a role in celastrol-mediated suppression of synovial fibroblasts of rheumatoid arthritis patients and experimental arthritis in rats. Br J Pharmacol 2019; 176:2922–2944. doi: 10.1111/bph.14718.
doi: 10.1111/bph.14718
Kuttapitiya A, Assi L, Laing K, Hing C, Mitchell P, Whitley G, et al. Microarray analysis of bone marrow lesions in osteoarthritis demonstrates upregulation of genes implicated in osteochondral turnover, neurogenesis and inflammation. Ann Rheum Dis 2017; 76:1764–1773. doi: 10.1136/annrheumdis-2017-211396.
doi: 10.1136/annrheumdis-2017-211396
Chizzolini C. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol 2008; 20:707–712. doi: 10.1097/BOR.0b013e32830c45ae.
doi: 10.1097/bor.0b013e32830c45ae
Gourh P, Agarwal SK, Martin E, Divecha D, Rueda B, Bunting H, et al. Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J Autoimmun 2010; 34:155–162. doi: 10.1016/j.jaut.2009.08.014.
doi: 10.1016/j.jaut.2009.08.014
Pimentel-Santos FM, Ligeiro D, Matos M, Mourao AF, Costa J, Santos H, et al. Whole blood transcriptional profiling in ankylosing spondylitis identifies novel candidate genes that might contribute to the inflammatory and tissue-destructive disease aspects. Arthritis Res Ther 2011; 13:R57doi: 5710.1186/ar3309.
doi: 5710.1186/ar3309
Fox RI. Sjogren's syndrome. Lancet 2005; 366:321–331. doi: 10.1016/S0140-6736(05)66990-5.
doi: 10.1016/s0140-6736(05)66990-5
Hu S, Vissink A, Arellano M, Roozendaal C, Zhou H, Kallenberg CGM, et al. Identification of autoantibody biomarkers for primary Sjogren's syndrome using protein microarrays. Proteomics 2011; 11:1499–1507. doi: 10.1002/pmic.201000206.
doi: 10.1002/pmic.201000206
Davis NA, Lareau CA, White BC, Pandey A, Wiley G, Montgomery CG, et al. Encore: genetic association interaction network centrality pipeline and application to SLE exome data. Genet Epidemiol 2013; 37:614–621. doi: 10.1002/gepi.21739.
doi: 10.1002/gepi.21739
Wang XQ, Lei DY, Ding J, Liu S, Tao L, Zhang F, et al. A DNA-methylated sight on autoimmune inflammation network across RA, pSS, and SLE. J Immunol Res 2018; 2018:4390789doi: 10.1155/2018/4390789.
doi: 10.1155/2018/4390789
Alexander JJ, Saxena AK, Bao LH, Jacob A, Haas M, Quigg RJ. Prominent renal expression of a murine leukemia retrovirus in experimental systemic lupus erythematosus. J Am Soc Nephrol 2002; 13:2869–2877. doi: 10.1097/01.Asn.0000036868.73317.7a.
doi: 10.1097/01.asn.0000036868.73317.7a
Tranter M, Helsley RN, Paulding WR, McGuinness M, Brokamp C, Haar L, et al. Coordinated post-transcriptional regulation of Hsp70.3 gene expression by microRNA and alternative polyadenylation. J Biol Chem 2011; 286:29828–29837. doi: 10.1074/jbc.M111.221796.
doi: 10.1074/jbc.m111.221796
Shi LH, Zhang Z, Yu AM, Wang W, Wei Z, Akhter E, et al. The SLE transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of non-coding and coding RNAs. Plos One 2014; 9:e93846doi: 10.1371/journal.pone.0093846.
doi: 10.1371/journal.pone.0093846
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295–306. doi: 10.1111/j.1538-7836.2006.01753.x.
doi: 10.1111/j.1538-7836.2006.01753.x
Yalavarthi S, Gould TJ, Rao AN, Mazza LF, Morris AE, Nunez-Alvarez C, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol 2015; 67:2990–3003. doi: 10.1002/art.39247.
doi: 10.1002/art.39247
Knight JS, Meng H, Coit P, Yalavarthi S, Sule G, Gandhi AA, et al. Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. JCI Insight 2017; 2:93897doi: 10.1172/jci.insight.93897.
doi: 10.1172/jci.insight.93897
Liu B, Su Y, Li T, Yuan W, Mo X, Li H, et al. CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation. Oncotarget 2015; 6:41092–41107. doi: 10.18632/oncotarget.5732.
doi: 10.18632/oncotarget.5732
Morrison AC, Felix JF, Cupples LA, Glazer NL, Loehr LR, Dehghan A, et al. Genomic variation associated with mortality among adults of European and African Ancestry with heart failure the cohorts for heart and aging research in genomic epidemiology consortium. Circ-Cardiovasc Gene 2010; 3:248–264. doi: 10.1161/Circgenetics.109.895995.
doi: 10.1161/circgenetics.109.895995
Zhang WJ, Qi H, Mo XN, Sun QY, Li T, Song QS, et al. CMTM8 is frequently downregulated in multiple solid tumors. Appl Immunohisto Mol Morphol 2017; 25:122–128. doi: 10.1097/Pai.0000000000000274.
doi: 10.1097/pai.0000000000000274
Liu Q, Su Y, Jiang GC, Zhou ZL, Liu BC, Bu L, et al. Change of CMTM7 expression, a potential tumor suppressor, is associated with poor clinical outcome in human non-small cell lung cancer. Chin Med J 2013; 126:3006–3012. doi: 10.3760/cmaj.issn.0366-6999.20123625.
doi: 10.3760/cmaj.issn.0366-6999.20123625
Rahat MA, Shakya J. Parallel aspects of the microenvironment in cancer and autoimmune disease. Mediat Inflamm 2016; 2016:4375120doi: 10.1155/2016/4375120.
doi: 10.1155/2016/4375120
Del Prete A, Allavena P, Santoro G, Fumarulo R, Corsi MM, Mantovani A. Molecular pathways in cancer-related inflammation. Biochem Medica 2011; 21:264–275. doi: 10.11613/bm.2011.036.
doi: 10.11613/bm.2011.036